Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 ADNI2 - Private Partner Scientific Board (PPSB) Susan De Santi (Piramal Pharma, Inc.), PPSB Chair.

Published byAgatha Kelly Modified over 9 years ago

Similar presentations

Presentation on theme: "1 ADNI2 - Private Partner Scientific Board (PPSB) Susan De Santi (Piramal Pharma, Inc.), PPSB Chair."— Presentation transcript:

1 1 ADNI2 - Private Partner Scientific Board (PPSB) Susan De Santi (Piramal Pharma, Inc.), PPSB Chair

2 Current ADNI 2 PPSB Partners

3 Dorothy Jones-Davis Scientific Project Manager, Neuroscience Foundation for the NIH (301) 594-9255 djones-davis@fnih.org FNIH Coordination and Organization

4 ADNI Cores MRI Cliff Jack PET Bill Jagust Biochemical Biomarker Les Shaw and John Trojanowski Biostatistics Laurel Beckett Clinical Ron Petersen & Paul Aisen Genetics Andy Saykin Neuropathology John Morris Publications Robert Green Pat Cole Adam Schwarz Holly Soares Johannes Streffer TBD Veronika Logovinsky Nandini Raghavan Nadeem Sarwar Leanne Munsie Enchi Liu Robert Paul Mark Schmidt Greg Klein Lee Honigberg RARC Tom Montine Enchi Liu Holly Soares PPSB Core Liaisons ADNI PI Mike Weiner PPSBPPSB PPSB working groups Biofluid Biomarkers WG Johan Luthman Clinical Endpoints WG Veronika Logovinsky, Nandini Raghavan 1.pAD/MCI Endpoints and Methods 2.Novel Tests for pre-MCI 3.List of Datasets 4.Computerized Cognitive Batteries PET Endpoints WG Mark Schmidt PPSB Chair Susan De Santi 2015 Informatics Art Toga

5 A goal of ADNI is to develop and validate methods for clinical trials PPSB has formalized a DD process for the selection of measures to be included in ADNI 3 and provide recommendations to ADNI Core leaders (e.g. clinical, cognitive, imaging, biomarkers, biofluids, etc.) An increase in commercial and competitive measures and markers being considered for ADNI; adding and subtracting precompetitive measures Inclusion of measures into ADNI 3 will be based on a solid analysis using objective criteria outline key criteria for consideration of measures assure transparency on how measures are identified, vetted and selected define clear, efficient timeline (e.g. < 4 months) avoid duplication of efforts achieve alignment for the final recommendation DD team assembled (no links to possible providers) for full vetted process Academics and industry scientists are working together Due Diligence (DD) Process for ADNI 3

6 Questions?

Download ppt "1 ADNI2 - Private Partner Scientific Board (PPSB) Susan De Santi (Piramal Pharma, Inc.), PPSB Chair."

Similar presentations

NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI) NEWMEDS Novel MEthods.

NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI) NEWMEDS Novel MEthods.
Forsyth.schoolwires.com Ways People Use Grades Communication to parents and others Student self-evaluation Select, identify, or group students Provide.

Forsyth.schoolwires.com Ways People Use Grades Communication to parents and others Student self-evaluation Select, identify, or group students Provide.
Connecting with Industry Heather M Wallace Industrial Liaison Group Medical Sciences and Medicine.

Connecting with Industry Heather M Wallace Industrial Liaison Group Medical Sciences and Medicine.
E5 Experiences in Japan Examples with unfavorable outcome How can we improve? Masuhiro Kato, PhD Chair, EFPIA Japan Technical Subcommittee (AstraZeneca.

E5 Experiences in Japan Examples with unfavorable outcome How can we improve? Masuhiro Kato, PhD Chair, EFPIA Japan Technical Subcommittee (AstraZeneca.
December, 2010. NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.
The Open Innovation Center Susie Stephens, Principal Research Scientist, Eli Lilly.

The Open Innovation Center Susie Stephens, Principal Research Scientist, Eli Lilly.
Facilities Management 2013 Manager Enrichment Program U.Va.’s Strategic Planning Initiatives Colette Sheehy Vice President for Management and Budget December.

Facilities Management 2013 Manager Enrichment Program U.Va.’s Strategic Planning Initiatives Colette Sheehy Vice President for Management and Budget December.
U.S. Department of the Interior U.S. Geological Survey USGS Digital Aerial Mapping Camera Status CRSS/ASPRS Specialty Conference October 2007 USGS Remote.

U.S. Department of the Interior U.S. Geological Survey USGS Digital Aerial Mapping Camera Status CRSS/ASPRS Specialty Conference October 2007 USGS Remote.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
ADNI 3 Clinical Core Plans

ADNI 3 Clinical Core Plans
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.

Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.

Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.
Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.
Jacquie Westwood UK Genetic Testing Network.  Approving UKGTN member labs who provide quality assured tests  Acknowledgment – UKGTN Laboratory Membership.

Jacquie Westwood UK Genetic Testing Network.  Approving UKGTN member labs who provide quality assured tests  Acknowledgment – UKGTN Laboratory Membership.
Genetics Core Update & Planning ADNI-2 Steering Committee Philadelphia April 28, 2014 Andy Saykin Indiana University

Genetics Core Update & Planning ADNI-2 Steering Committee Philadelphia April 28, 2014 Andy Saykin Indiana University
2014 “Towards an HIV Cure” symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San.

2014 “Towards an HIV Cure” symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San.
ADNI Private Partner Scientific Board (PPSB) Update Susan De Santi, PhD 2015 Chairperson WW ADNI Meeting July 17, 2015.

ADNI Private Partner Scientific Board (PPSB) Update Susan De Santi, PhD 2015 Chairperson WW ADNI Meeting July 17, 2015.
1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.

1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.
A PPP managed by FNIH Partners are NIH, FDA, CMS, and private industry Barbara B. Mittleman, M.D. Director, NIH PPP Program Bioinformatics Forum March.

A PPP managed by FNIH Partners are NIH, FDA, CMS, and private industry Barbara B. Mittleman, M.D. Director, NIH PPP Program Bioinformatics Forum March.
1 Collaborative Provision and External Examining Nicola Clarke Centre for Academic Standards and Quality Enhancement (CASQE)

1 Collaborative Provision and External Examining Nicola Clarke Centre for Academic Standards and Quality Enhancement (CASQE)

Similar presentations

Ads by Google